Alentis Therapeutics
Manufacturing · Switzerland · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Hegenheimermattweg 167a, Allschwil, Base...Website
www.alentis.chRevenue
$16.9 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Alentis Therapeutics
Alentis Therapeutics is a clinical-stage biotech company dedicated to developing innovative therapies targeting cancer and fibrosis through Claudin-1. They focus on advancing a pipeline of anti-Claudin-1 antibody-drug conjugates (ADCs) and monoclonal antibodies, aiming to unlock the potential of this therapeutic target. Their clinical candidates include ADC ALE.P02 for squamous cancers and monoclonal antibody lixudebart for organ fibrosis. The company is supported by a strong leadership team and aims to deliver transformative treatments for patients in need.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Alentis Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Alentis Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Alentis Therapeutics
Funding: Get notified immidiatlly once Alentis Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Alentis Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Click to see if Alentis Therapeutics had a recent Job posting/layoffs
Alentis Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Alentis Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Alentis Therapeutics recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Alentis Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Alentis Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Alentis Therapeutics.
Alentis Therapeutics financials insights
Gather financial insights about Alentis Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$12.5M
2021
Series B
$67M
2023
Series C
$105M
2024
Series D
$181.4M
Alentis Therapeutics Tech Stack
A closer look at the technologies used by Alentis Therapeutics
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Alentis Therapeutics News & Media
Alentis Announces Positive Topline Results from Two Studies of Lixudebart (ALE.F02) in Patients with ANCA-RPGN and Advanced Liver Fibrosis
BASEL, Switzerland--(BUSINESS WIRE)--Demonstrated Robust Dose-Dependent Target Engagement, Preliminary Evidence of Improved Organ Function and a Favorable Safety ProfileFollow the Money: Seaport Therapeutics Glyph Platform, Pathos AI Expansion, More
Stay on top of emerging IT trends in biomedicine. Read the latest news on genomics, computational science, and more. Get recent updates today!Alentis Receives FDA Fast Track Designation for ALE.P02 for the Treatment of CLDN1+ Squamous Solid Tumors
BASEL, Switzerland--(BUSINESS WIRE)-- #ADC--The designation is granted for the treatment of advanced or metastatic CLDN1+ squamous cancers irrespective of the organ of origin
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Alentis Therapeutics
Sign Up For FreeTo access detailed company insights
Alentis Therapeutics is a clinical-stage biotech company dedicated to developing innovative therapies targeting cancer and fibrosis through Claudin-1. They focus on advancing a pipeline of anti-Claudin-1 antibody-drug conjugates (ADCs) and monoclonal antibodies, aiming to unlock the potential of this therapeutic target. Their clinical candidates in... Read More
